Literature DB >> 21632911

Statin myopathy: a common dilemma not reflected in clinical trials.

Genaro Fernandez1, Erica S Spatz, Charles Jablecki, Paul S Phillips.   

Abstract

Although statins are remarkably effective, they are still underprescribed because of concerns about muscle toxicity. We review the aspects of statin myopathy that are important to the primary care physician and provide a guide for evaluating patients on statins who present with muscle complaints. We outline the differential diagnosis, the risks and benefits of statin therapy in patients with possible toxicity, and the subsequent treatment options.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21632911     DOI: 10.3949/ccjm.78a.10073

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN: 0891-1150            Impact factor:   2.321


  59 in total

1.  Statin-induced calcific Achilles tendinopathy in rats: comparison of biomechanical and histopathological effects of simvastatin, atorvastatin and rosuvastatin.

Authors:  Ferda Kaleağasıoğlu; Ercan Olcay; Vakur Olgaç
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2015-08-15       Impact factor: 4.342

2.  Mitophagy protects against statin-mediated skeletal muscle toxicity.

Authors:  Mridula Ramesh; Juliane C Campos; Pamela Lee; Yang Song; Genaro Hernandez; Jon Sin; Kyle C Tucker; Hannaneh Saadaeijahromi; Michael Gurney; Julio C B Ferreira; Allen M Andres
Journal:  FASEB J       Date:  2019-08-23       Impact factor: 5.191

3.  Effect of simvastatin on sensorial, motor, and morphological parameters in sciatic nerve crush induced-neuropathic pain in rats.

Authors:  Claudia Rita Corso; Daniel Fernandes Martins; Stephanie Carvalho Borges; Olair Carlos Beltrame; José Ederaldo Queiroz Telles; Nilza Cristina Buttow; Maria Fernanda de Paula Werner
Journal:  Inflammopharmacology       Date:  2017-11-29       Impact factor: 4.473

4.  Experimental nonalcoholic steatohepatitis increases exposure to simvastatin hydroxy acid by decreasing hepatic organic anion transporting polypeptide expression.

Authors:  John D Clarke; Rhiannon N Hardwick; April D Lake; Mark J Canet; Nathan J Cherrington
Journal:  J Pharmacol Exp Ther       Date:  2014-01-08       Impact factor: 4.030

5.  Effects of fluvastatin and coenzyme Q10 on skeletal muscle in normo- and hypercholesterolaemic rats.

Authors:  J Vincze; Á Jenes; M Füzi; J Almássy; R Németh; G Szigeti; B Dienes; Z Gaál; P Szentesi; I Jóna; P Kertai; G Paragh; L Csernoch
Journal:  J Muscle Res Cell Motil       Date:  2015-04-29       Impact factor: 2.698

Review 6.  A comprehensive review and meta-analysis of risk factors for statin-induced myopathy.

Authors:  Khoa A Nguyen; Lang Li; Deshun Lu; Aida Yazdanparast; Lei Wang; Rolf P Kreutz; Elizabeth C Whipple; Titus K Schleyer
Journal:  Eur J Clin Pharmacol       Date:  2018-05-22       Impact factor: 2.953

Review 7.  Myopathy in older people receiving statin therapy: a systematic review and meta-analysis.

Authors:  Roli B Iwere; Jonathan Hewitt
Journal:  Br J Clin Pharmacol       Date:  2015-07-22       Impact factor: 4.335

Review 8.  Do statins cause diabetes?

Authors:  Mark R Goldstein; Luca Mascitelli
Journal:  Curr Diab Rep       Date:  2013-06       Impact factor: 4.810

Review 9.  The impact of statins on physical activity and exercise capacity: an overview of the evidence, mechanisms, and recommendations.

Authors:  Allyson M Schweitzer; Molly A Gingrich; Thomas J Hawke; Irena A Rebalka
Journal:  Eur J Appl Physiol       Date:  2020-04-04       Impact factor: 3.078

10.  Perspective on the 2013 American Heart Association/American College of Cardiology guideline for the use of statins in primary prevention of low-risk individuals.

Authors:  Jan L Breslow
Journal:  Circ Res       Date:  2014-02-28       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.